⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20496299 | 0.69 | CA12 (0.39) | — | |
| SCHEMBL4487168 | 0.69 | — | — | |
| SCHEMBL26587 | 0.69 | — | — | |
| SCHEMBL2125025 | 0.69 | — | — | |
| SCHEMBL5502105 | 0.67 | — | — | |
| SCHEMBL9022244 | 0.67 | — | — | |
| SCHEMBL17208188 | 0.67 | — | — | |
| SCHEMBL19686201 | 0.67 | — | — | |
| SCHEMBL5879487 | 0.67 | — | — | |
| Trimethylammonium SCHEMBL27713570 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7875 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426781-B1 | MICRORNAS AND METHODS OF THEIR USE | US HEALTH (US) | 2024-06-26 | — | — | EP | claimed |
| US-11970711-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-30 | — | — | US | claimed |
| EP-4314297-A1 | TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE | Specific Biologics Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| WO-2024013361-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | PROQR THERAPEUTICS II B.V. (NL) | 2024-01-18 | — | — | WO | claimed |
| CN-117083385-A | Targeting oncogenic mutations with double-cleaving endonucleases | 特定生物制品公司 | 2023-11-17 | — | — | CN | claimed |
| US-11795472-B2 | RNA-guided nucleic acid modifying enzymes and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-24 | — | — | US | claimed |
| WO-2023201203-A2 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-19 | — | — | WO | claimed |
| EP-4240839-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | Specific Biologics Inc. (CA) | 2023-09-13 | — | — | EP | claimed |
| CN-116669775-A | Gene editing with modified endonucleases | 特定生物制品公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2023107531-A2 | ANTISENSE OLIGONUCLEOTIDE DRUG TARGETS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-15 | — | — | WO | claimed |
| EP-1263765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-11 | — | — | EP | claimed |
| JP-2002526093-A | — | — | 2002-08-20 | — | — | JP | claimed |
| WO-2001072765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| EP-1119579-A1 | ANTISENSE MODULATION OF BCL-X EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-08-01 | — | — | EP | claimed |
| US-20010007025-A1 | Antisense modulation of bcl-x expression | ISIS PHARMACEUTICALS, INC. | 2001-07-05 | — | — | US | claimed |
| US-6214986-B1 | OLIGONUCLEOTIDE OF DEFINED NUCLEOTIDE SEQUENCE TARGETED TO HUMAN PROTEIN WHICH CONTROLS APOPTOSIS; ALTERS RATIOS OF ISOFORMS IN TISSUE; GENE EXPRESSION INHIBITION; SENSITIZING CELLS TO APOPTOTIC STIMULI | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | claimed |
| US-6210892-B1 | HYBRIDIZING AN ANTISENSE COMPOUND HAVING A 2' SUGAR, MORPHOLINO, OR PEPTIDE NUCLEIC ACID MODIFICATION TO TARGET MESSENGER RNA TO CHANGE ITS PROCESSING INCLUDING SPLICING, POLYADENYLATION OR STABILITY | ISIS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | claimed |
| WO-2001002417-A1 | NUCLEOTIDE MONOMER CONTAINING SIX-MEMBERED AZARSUGAR AND ANTISENSE OLIGOMERS THEREOF | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2001-01-11 | — | — | WO | claimed |
| WO-2000020432-A1 | ANTISENSE MODULATION OF BCL-X EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | claimed |
| WO-2000004189-A1 | MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |